

Alterations in protein kinase A substrate specificity as a potential cause of Cushing's Syndrome

Bathon, Kerstin; Wigand, Isabel; Vanselow, Jens T.; Ronchi, Cristina; Sbiera, Silviu; Schlosser, Andreas; Calebiro, Davide; Fassnacht, Martin

DOI:

[10.1210/en.2018-00775](https://doi.org/10.1210/en.2018-00775)

License:

Other (please specify with Rights Statement)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Bathon, K, Wigand, I, Vanselow, JT, Ronchi, C, Sbiera, S, Schlosser, A, Calebiro, D & Fassnacht, M 2019, 'Alterations in protein kinase A substrate specificity as a potential cause of Cushing's Syndrome', *Endocrinology*, vol. 160, no. 2, pp. 447-459. <https://doi.org/10.1210/en.2018-00775>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

This is a pre-copyedited, author-produced PDF of an article accepted for publication in *Endocrinology* following peer review. The version of record Kerstin Bathon, Isabel Weigand, Jens T Vanselow, Cristina L Ronchi, Silviu Sbiera, Andreas Schlosser, Martin Fassnacht, Davide Calebiro; Alterations in Protein Kinase A Substrate Specificity as a Potential Cause of Cushing Syndrome, *Endocrinology*, Volume 160, Issue 2, 1 February 2019, Pages 447–459, <https://doi.org/10.1210/en.2018-00775> is available online at: <https://doi.org/10.1210/en.2018-00775>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Alterations in Protein Kinase A Substrate Specificity as a Potential Cause of Cushing's Syndrome

Kerstin Bathon¹, Isabel Weigand², Jens T. Vanselow³, Cristina L. Ronchi^{2,5,6}, Silviu Sbiera²,
Andreas Schlosser³, Martin Fassnacht^{2,4}, Davide Calebiro^{1,5,7*}

¹ Institute of Pharmacology and Toxicology and Bio-Imaging Center, University of Würzburg, 97078 Würzburg, Germany

² Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, 97080 Würzburg, Germany

³ Rudolf Virchow Center, University of Würzburg, 97080 Würzburg, Germany

⁴ Central Laboratory, University Hospital Würzburg, 97080 Würzburg, Germany

⁵ Institute of Metabolism and Systems Research (IMSR), University of Birmingham, B15 2TT Birmingham, UK

⁶ Centre for Endocrinology, Diabetes and Metabolism (CEDAM), Birmingham Health Partners, B15 2TT Birmingham, UK

⁷ Centre of Membrane Proteins and Receptors (COMPARE), B15 2TT Birmingham, UK

Short title: Mutations in adrenal Cushing alter PKA specificity

Keywords: PKA, Cushing's syndrome, *PRKACA* mutations

* Address correspondence and material requests to:

Davide Calebiro MD PhD DSc

Institute of Metabolism and Systems Research

College of Medical and Dental Sciences

Edgbaston

Birmingham

B15 2TT

Tel. +44 (0) 121 414 3928

Fax. +44 (0) 121 415 8712

email. davide.calebiro@toxi.uni-wuerzburg.de

Funding

This study was supported by the IZKF Würzburg (grant B-281 to D.C. and M.F.), the ERA-NET “E-Rare” (grant 01GM1407B to M.F. and D.C.) and the Deutsche Forschungsgemeinschaft (SFB/Transregio 166–Project C1 to D.C. and SFB/Transregio 205/1 to M.F.). KB was partially supported by a grant of the German Excellence Initiative to the Graduate School of Life Sciences, University of Würzburg. The tumor samples were stored at the Interdisciplinary Bank of Biomaterials and Data of the University Hospital of Würzburg and the Julius Maximilian University of Würzburg (idbw). The implementation of idbw has been supported by a grant of the Federal Ministry for Education and Research (Grant number FKZ: 01EY1102).

Disclosure Summary: The authors have nothing to disclose.

Abstract

Cushing's syndrome is a severe endocrine disorder of cortisol excess, associated with major metabolic and cardiovascular sequelae. We recently identified somatic mutations in the gene (*PRKACA*) encoding the catalytic α ($C\alpha$) subunit of protein kinase A (PKA) to be responsible for cortisol-producing adrenocortical adenomas (CPAs), which are a major cause of Cushing's syndrome. In spite of previous studies on the two initially identified mutations (L206R, 199_200insW), the mechanisms of action of the clinically highly relevant *PRKACA* mutations remain poorly understood. Here, by investigating a large panel of *PRKACA* mutations including all those identified so far in Cushing's syndrome, we unexpectedly find that not all mutations interfere with the binding of regulatory (R) subunits as previously hypothesized. Since several mutations lie in a region of PKA $C\alpha$ involved in substrate recognition, we have investigated their consequences on substrate specificity by quantitative phosphoproteomics. We find that all three mutations analyzed (L206R, 200_201insV and d244-248+E249Q) cause major changes in the preference of PKA for its targets, leading to hyperphosphorylation of several PKA substrates, including most notably histone H1.4 at Ser36, which is required for and promotes mitosis. This is reflected by a 9-fold hyperphosphorylation of H1.4 in CPAs carrying the L206R mutation. Thus, our findings suggest that besides hampering binding to R subunits, *PRKACA* mutations act via altering PKA substrate specificity. These findings shed new light on the molecular events leading to Cushing's syndrome and provide an illustrative example of how mutations altering substrate specificity of a protein kinase might cause human disease.

Introduction

Cushing's syndrome is an endocrine disease characterized by cortisol excess. If not promptly recognized and treated, it is associated with severe morbidity and increased mortality, mostly due to metabolic and cardiovascular sequelae, such as diabetes mellitus, osteoporosis and hypertension (1,2). Beside ACTH-producing pituitary adenomas, cortisol-producing adenomas of the adrenal are the major cause of endogenous Cushing's syndrome (3).

Protein kinase A (PKA) is the main intracellular mediator of the ubiquitous second messenger cyclic AMP (cAMP), which is produced in response to several hormones and neurotransmitters (4,5). In its inactive state, PKA is a tetrameric complex composed of two regulatory (R) and two catalytic (C) subunits (5), which exist in different isoforms – three for C (α , β , γ) and four for R ($I\alpha$, $I\beta$, $II\alpha$, $II\beta$) subunits, each encoded by a separate gene (6). Additionally, protein kinase X (PrKX) can also form holoenzymes with R subunits (7). In the inactive complex, two short linear segments emanating from each R subunit, known as inhibitory sequences, act as substrates (RII) or pseudo-substrates (RI) that occupy the active site clefts of the C subunits, thus preventing the access of other substrates (5,8,9); this keeps PKA in the inactive state (5,8,9). Binding of cAMP to two distinct sites on each R subunit induces their dissociation from the C subunits, allowing the C subunits to phosphorylate a large number of PKA substrates located in both the cytosol and the nucleus (5,8,9).

Our group has recently discovered that somatic mutations in the gene coding for the $C\alpha$ subunit of PKA (*PRKACA*) are responsible for Cushing's syndrome due to cortisol-producing adrenocortical adenomas (CPAs) (10-13). These findings have been independently confirmed by other groups (14-18). Very recently, rare mutations in the gene coding for the $C\beta$ subunit of PKA (*PRKACB*) have also been found in CPAs (19). Between 23 and 67% of all CPAs carry a recurrent mutation (L206R) of a residue in the $C\alpha$ subunit that is involved in the interaction with the R subunits (10,11,14-16). By screening a large group of CPAs, we

have in the meantime identified six additional *PRKACA* mutations (199_200insW, S213R+insILLR, 200_201insV, W197R, d244-248+E249Q and E32V) in unilateral adenomas of patients affected by overt Cushing's syndrome (10-12). With one exception (E32V), all identified mutations lie in a hot spot region on the surface of the C α subunit that is adjacent to the active site cleft and faces the R subunit (12).

Whereas all previous studies provide strong evidence for a causal role of *PRKACA* mutations, the mechanisms linking these mutations to increased cell proliferation and cortisol secretion in adrenocortical cells are still debated (10,14-16). One of the initial studies suggested that the L206R mutation increases PKA activity by enhancing substrate interaction and/or the catalytic activity of the enzyme (14). In contrast, two other studies suggested that the L206R mutation might prevent binding of the R subunit (15,16). In strong support of this possibility, we subsequently demonstrated that the two initially identified mutations (L206R and 199_200insW) interfere with the formation of a stable complex with R subunits, thus rendering mutated C α subunits constitutively active (13). However, we did not observe increased catalytic activity (13). Whereas these data indicate that a reduced interaction with R subunits is likely involved in the pathogenesis of Cushing's syndrome – at least in the case of the two investigated *PRKACA* mutations (L206R and 199_200insW) – additional mechanisms might play an equally important role.

Here, we report a comprehensive functional characterization of all *PRKACA* mutations identified so far. Unexpectedly, our results indicate that besides interfering with the binding of R subunits, *PRKACA* mutations cause major changes in the preference of PKA for its targets, leading to hyperphosphorylation of several PKA substrates, including most notably histone H1.4 at Ser36, which is required for and promotes mitosis (20).

Methods

Plasmids

Plasmids encoding human $R1\alpha$, $R11\beta$ and $R11\beta$ -FLAG were described earlier (13). A plasmid encoding human wild-type $C\alpha$ was purchased from Origene. Mutations in the coding sequence of $C\alpha$ were introduced by PCR as previously described (10). To generate a plasmid encoding a FLAG-tagged $R1\alpha$ subunit, a fragment containing the entire coding sequence of the human $R1\alpha$ subunit was amplified by PCR with a forward primer containing the FLAG tag (amino-acid sequence DYKDDDDA) and a HindIII site at the 5' and a reverse primer containing a NotI site at the 3'. This fragment was subsequently cloned between the HindIII and NotI sites of pcDNA3.

Tumor tissue

A total of 8 snap-frozen tumor specimens from CPAs were investigated. All samples were collected at the University Hospital of Würzburg. Six of these samples had been included in previous reports from our group: three in Ronchi et al. (12) and three in Beuschlein et al. (10). According to our previous sequencing data, four CPA samples harbored somatic *PRKACA* mutations. In particular, three samples from patients with overt Cushing's syndrome presented a L206R substitution and one sample from a patient with mild autonomous cortisol secretion (subclinical Cushing's syndrome) presented a d244-248+E249Q mutation. The four remaining CPAs were *PRKACA* wild-type. The collection of the clinical data and the biomaterial for this retrospective study was approved by the ethics committee of the University of Würzburg (approvals no. 93/02 and 88/11). Written informed consent was obtained from all patients.

Cell culture and transfection

HEK293A cells were obtained from ATCC. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FCS, 0.1 mg/ml streptomycin and 100

U/ml penicillin at 37 °C, 5% (vol/vol) CO₂. HEK293A cells were seeded at a density of 3.5x10⁶ cells/15-cm Petri dish, 1.2 x 10⁶ cells/10-cm Petri dish or 0.25 x 10⁶ cells/well onto 6-well plates and allowed to grow for 24 h, after which they were transfected with the Effectene transfection kit (Qiagen) according to the manufacturer's protocol. A 1:8 ratio of transfected C and R subunit DNAs was used to favor association between C and R subunits (10). All experiments were performed 48 h after transfection. For SILAC labeling, the cells were grown in light (Lys0, Arg0) or heavy (Lys8, Arg10) labeled DMEM supplemented with 10% dialyzed FCS and 0.1 mg/ml streptomycin and 100 U/ml penicillin for at least 6 passages before the experiment.

Preparation of cell lysates

Cells were washed with ice-cold phosphate-buffered saline (PBS), scraped off plates, and resuspended in 300 µl 5/2 buffer (5 mM Tris-HCl, 2 mM EDTA, pH 7.4). Thereafter, samples were homogenized using an Ultraturrax device for 20 s on ice and centrifuged at 50,000 x g for 30 min at 4 °C to remove membranes.

Preparation of total cell lysates

Cells were washed once with PBS. Then, 2 ml of lysis buffer (8M urea, 1 mM sodium vanadate, 2.5 mM pyrophosphate, 1 mM β-glycerophosphate, 20mM HEPES, pH 8.0) supplemented with the cOmplete Mini EDTA-free protease inhibitor cocktail (Roche) were added to each 15-cm Petri dish and the cells were scraped into the buffer. Cell suspensions were sonicated three times for 15 sec each and lysates were cleared by centrifugation at 4,000 rpm for 1 h at 15 °C.

PKA activity assay

PKA catalytic activity was measured on cell lysates using the PepTag non-radioactive cAMP-dependent protein kinase assay (Promega), which uses fluorescent kemptide as a

substrate, following the manufacturer's instructions. Images of the gels were acquired with a gel documentation system (Herolab) and analyzed using the ImageJ software (<http://rsbweb.nih.gov/ij>). Endogenous PKA activity was subtracted and values were normalized to the value of the stimulated wild-type.

Co-immunoprecipitation

Cells were lysed with a buffer containing 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 20 mM Tris-HCl, pH 7.5, supplemented with cOmplete Mini protease inhibitor cocktail (Roche). Lysates were centrifuged at 20,000 x *g* for 10 min at 4 °C. Supernatants were transferred to a new vial and incubated with protein-A sepharose for 2 h at 4 °C under continuous rotation. Protein-A sepharose was preincubated with a mouse monoclonal anti-FLAG antibody (Sigma-Aldrich, # F3165). Preincubations were performed overnight at 4 °C under continuous rotation. After the incubation of protein-A sepharose with the cell lysates, samples were washed 5 times with lysis buffer. Proteins were recovered from protein-A sepharose by addition of Laemmli buffer, followed by incubation at 95 °C for 3 min. After Western blot analysis and quantification, the amount of C α was normalized to that in the wild-type sample.

Histone extraction

Histones were acid-extracted from cells and CPA samples as described by Shechter et al. (21). Briefly, harvested cells or Douncer-homogenized tissue samples were lysed in a hypotonic lysis buffer (150 mM Tris/HCl, 1 mM KCl, 1.5 mM MgCl₂, 1 mM DTT, pH 8.0) supplemented with 0.5 µg/ml leupeptin, 2 µg/ml aprotinin, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), the cOmplete Mini protease inhibitor cocktail (Roche) and a phosphatase inhibitor cocktail (Roche). Lysates were then acid-extracted with H₂SO₄ for 30 min followed by precipitation with trichloroacetic acid and resuspension in H₂O.

Western blot analysis

Samples were mixed with Laemmli buffer and incubated at 95 °C for 3 min. Proteins were separated by electrophoresis on either a 10% or 15% (for histone H1.4) SDS polyacrylamide gel and electro-transferred to a PVDF membrane (Merck Millipore). Membranes were blocked with Tris-buffered saline supplemented with 1% Tween and 5% skim milk powder or bovine serum albumin (antibodies detecting phosphoproteins) for 1 hour at RT, and incubated overnight at 4 °C with the indicated primary antibody, followed by incubation with horseradish peroxidase-conjugated secondary antibodies for 1 h at RT. PKA C α subunits were detected with a rabbit polyclonal antibody (Cell Signaling #4782, 1:7,000 dilution). FLAG-tagged R subunits were detected using a rabbit monoclonal anti-FLAG antibody (Sigma-Aldrich, #F7425, 1:4,000 dilution). PKA RI α subunits were detected using a mouse monoclonal antibody (BD Transduction Lab., #610609, 1:1,000 dilution) and RII β subunits with a mouse monoclonal antibody (BD Transduction Lab., #610625, 1:2,000 dilution). Phosphorylated PKA substrates were detected using a rabbit polyclonal antibody (Cell Signaling, #9621, 1:1,000 dilution). A rabbit polyclonal antibody (ThermoFisher, #PA5-31908, 1:2,000 dilution) and a rabbit polyclonal antibody (ThermoFisher, #PA5-31907, 1:1,000 dilution) was used for total histone H1.4 and Ser36 phosphorylated histone H1.4, respectively.

Substrate specificity of PKA C α mutants *in silico*

The *in silico* prediction was done using the Kinase Substrate Prediction v 2.0 algorithm (22). This algorithm predicts substrate specificity based on the primary amino acid sequence of more than 488 human protein kinase catalytic domains and 10,000 known kinase–substrate phosphosite pairs. The algorithm computes a specificity matrix for a given kinase, or mutant thereof, where values indicate the relative preference for each amino acid at each position around the phosphoacceptor site. Only relevant changes are reported.

Substrate specificity of PKA C α mutants *in vitro*

Mutant and wild-type samples were labelled with heavy and light amino acids as described in cell culture and transfection. Before preparing total cell lysates, the cells were stimulated with 10 μ M forskolin for 30 min. Protein concentration of the total cell lysates were determined using the BCA assay. Before processing the samples for phosphoproteomics, an input sample for proteome analysis was taken, which was digested with trypsin and analysed by nano LC-MS/MS. For phosphoproteomics experiments, no more than 20 mg protein were used. Substrate specificity was assessed using the PTMScan Phospho-PKA Substrate Motif (RRXS*/T*) Kit (Cell Signaling, #5565) following the manufacturer's instructions – see Supplementary Data (23) for details. The dried peptides were stored at -20°C until the nano LC-MS/MS analysis.

Nano LC-MS/MS analysis

Nanoscale liquid chromatography coupled to tandem mass spectrometry (nano LC-MS/MS) analyses were performed on an Orbitrap Fusion system (Thermo Scientific) equipped with an EASY-Spray Ion Source and coupled to an EASY-nLC 1000 (Thermo Scientific). Peptides, resuspended in 2% acetonitrile and 0.1% formic acid, were loaded on a trapping column (2 cm x 75 μ m ID, PepMap C18, 3 μ m particles, 100 Å pore size) and separated on an EASY-Spray column (50 cm x 75 μ m ID, PepMap C18, 2 μ m particles, 100 Å pore size) with a 140-min linear gradient from 3% to 45% acetonitrile and 0.1 % formic acid.

Both MS and MS/MS scans were acquired on the Orbitrap analyzer with a resolution of 60,000 for MS scans and 15,000 for MS/MS scans. HCD fragmentation with 35% normalized collision energy was applied. A Top Speed data-dependent MS/MS method with a fixed cycle time of 3 s was used. Dynamic exclusion was applied with a repeat count of 1 and an exclusion duration of 60 s; singly charged precursors were excluded from selection. Minimum signal threshold for precursor selection was set to 5×10^4 . Predictive AGC was

used with AGC target values of 2×10^5 for MS scans and 5×10^4 for MS/MS scans. EASY-IC was used for internal calibration.

Raw data processing and database search

For raw-data processing, database searches and SILAC quantification, the MaxQuant software version 1.5.6.5 was used (24). The search was performed against the human UniProt reference proteome database (download date: 2016-12-09) plus a small database containing known immunoglobulin chains. Additionally, a database containing common contaminants (included in MaxQuant) was used. The search was performed with tryptic cleavage specificity and 3 allowed miscleavages. Results were filtered to a false-discovery rate (FDR) <1% on protein, peptide and phosphosite level and for modified peptides a minimum score of 40 and a minimum delta score of 6 were required. In addition to default settings, protein N-terminal acetylation, Gln to pyro-Glu formation (N-term. Q), oxidation (M) and phosphorylation (STY) were included as variable modifications; carbamidomethyl (C) was set as fixed modification. For SILAC quantification, light (Arg0/Lys0) and heavy (Arg10/Lys8) labeling were selected, with max. 4 labeled amino acids per peptide allowed; matching between runs was disabled.

For further data analysis in R, the MaxQuant "Phospho (STY) Sites" table was processed, and only phosphosites with a localization probability >0.75 and a PEP < 0.05 have been included. For each experiment, the distribution of log2-transformed heavy/light SILAC ratios were normalized to the first mode of the distribution. Data from replicate experiments were combined, and Student's t-test as well as limma p-values were calculated and corrected for multiple-hypothesis testing (Benjamini-Hochberg algorithm, FDR). In addition, boxplot outliers with values outside of the 1.5x and/or the 3x interquartile range (IQR) of the 1st or 3rd quartile (Q1 or Q3) were labeled as significant or highly significant, only if a replicate notch, defined as $1.58 \cdot \text{IQR} / \sqrt{\text{number of experiments}}$, was not overlapping with the median of all such notches.

233

234 **Motif logo**

235 For calculation of position weight matrices from the phosphoproteomics data, the web tool
236 plogo (<http://plogo.uconn.edu/>) (25) was used. Values were calculated relative to the
237 background amino acid frequencies in the human proteome. Motif logos were then
238 generated using the Weblogo software version 3.5.0 (26).

239

240 **Structures**

241 Protein structures were generated using PyMol version 1.7.4.5. PDB entries 3TNP (9) and
242 3TNQ (9) were used as templates for the structures of the PKA C α -RII β holoenzyme and
243 the C α subunit in complex with a phosphorylated substrate, respectively.

244

245 **Statistical analyses**

246 Statistical analyses were performed using the Prism 6 software (GraphPad). Values are
247 given as mean \pm s.e.m. Differences between two groups were assessed by two-tailed
248 Student's t-test. Differences among three or more groups were assessed by two-way
249 analysis of variance (ANOVA), followed by Bonferroni's post hoc test. Differences were
250 considered significant for P values < 0.05 .

Results

***PRKACA* mutations have variable effects on R subunit binding**

Through genetic screening of a large series of CPAs from patients with Cushing's syndrome, we have identified a total of 7 *PRKACA* mutations, including the most frequent L206R, with an overall prevalence in CPAs of about 40% (10-12). The results of all available studies to date are summarized in Table 1. With the exception of E32V, all mutations identified so far lie at a hot spot at the interface with the R subunit (Fig. 1). Since our previous data indicated that the two initially identified mutations (L206R and 199_200insW) interfere with the formation of a stable complex with the inhibitory RII β subunit (13), we first evaluated the interaction of all mutations identified so far with both RI α and RII β – the two main R subunit isoforms expressed in adrenocortical cells – by co-immunoprecipitation (Fig. 2 and Supplementary Data, Fig. S1 (23)).

As expected, we observed a robust co-immunoprecipitation of exogenously expressed wild-type C α with both RI α and RII β (Fig. 2 and Supplementary Data, Fig. S1 (23)). In the case of four mutants (199_200insW, L206R, 200_201_insV and S213R+insIIIR), we detected only faint signals in the presence of either RI α or RII β , indicating that the interaction with both R subunit isoforms was largely lost, consistent with our previous observations (13). Unexpectedly, however, two mutants (W197R and E32V) displayed normal binding to both RI α and RII β (Fig. 2, arrows). Of note, a previous report indicates that the W197R mutant cannot bind to R subunits unless they are stripped off of cAMP, a condition that is not occurring in intact cells (27). The d244-248+E249Q mutant had an interesting behavior as it showed normal binding to RII β but a complete lack of binding to RI α (Fig 2, arrow). With the exception of S213R+insIIIR, all C α mutants dissociated virtually completely from R subunits upon addition of cAMP (Fig. 2 and Supplementary Data, Fig. S1 (23)).

***PRKACA* mutations have variable effects on PKA activity**

277 Next, we investigated the activity of the C α mutants against the widely used synthetic
278 peptide substrate kemptide. In lysates obtained from HEK293A cells co-transfected with
279 wild-type or mutant C α subunits and either RI α or RII β , we observed a high variability among
280 the investigated C α mutants. A first group of mutants (199_200insW, L206R, W197R, d244-
281 248+E249Q and S213R+insIIIR) was characterized by increased basal activity against
282 kemptide at least in one condition (i.e. with RI α or RII β) (Fig. 3). The E32V mutant was
283 apparently behaving like wild-type C α (Fig. 3). The 200_201insV mutant was characterized
284 by a strongly reduced maximal activity (measured in the presence of cAMP) against
285 kemptide compared to wild-type C α (Fig. 3).

286 Unexpectedly, a different picture was observed when PKA activity was evaluated against
287 endogenous substrates in lysates of HEK293A cells transfected with the different C α
288 mutants and analyzed by Western blot analysis with an anti-phospho-PKA substrate
289 antibody (Supplementary Data, Fig. S2 (23)). In this assay, RII β but not RI α co-expression
290 was capable of buffering the activity of exogenous wild-type or mutant C α subunits,
291 consistent with previous observations (9). Therefore, we focused on the results obtained in
292 the presence of RII β . In cells co-transfected with RII β , two C α mutants (199_200insW and
293 L206R) showed strongly increased basal activity compared to wild-type C α (Supplementary
294 Data, Fig. S2 (23)). The remaining mutants were characterized by a variable degree of
295 increased basal activity compared to wild-type C α (Supplementary Data, Fig. S2 (23)).
296 Notably, in this assay, the 200_201insV mutant, which was characterized by a strongly
297 reduced maximal activity in the kemptide assay, could be stimulated by addition of the
298 adenylyl cyclase activator forskolin to a similar although slightly lower extent compared to
299 wild-type C α (Supplementary Data, Fig. S2 (23)). At a closer look, this analysis also
300 revealed potentially different phosphorylation patterns for the C α mutants compared to wild-
301 type C α as well as among the C α mutants (Supplementary Data, Fig. S2A, arrows (23)).
302 Altogether, these data suggested the possibility that the investigated *PRKACA* mutations

might alter the relative preference of PKA for its substrates, so that investigating a single synthetic substrate does not provide a satisfactory description of the activity of C α mutants against endogenous substrates.

***In silico* analysis of *PRKACA* mutations predicts changes in substrate specificity**

Our results suggested the possibility that *PRKACA* mutations might alter the preference of PKA for its substrates and, thus, cause a relative change in substrate specificity. This hypothesis was consistent with the location of most *PRKACA* mutations in a region of C α that is critical for substrate binding and recognition (27,28) (Fig. 1B). To further explore this possibility, we performed an *in silico* analysis using a protein kinase substrate prediction algorithm (22). The algorithm predicted relevant changes in substrate specificity for four mutants: 199_200insW, L206R, d244-248+E249Q and 200_201insV (Fig. 1B and Supplementary Data, Fig. S3 (23)). The largest change was predicted for the d244-248+E249Q mutant. For the S213R+insIILR mutant, the algorithm predicted only minor effects on substrate specificity, whereas no changes were predicted for the two remaining mutants (E32V, W197R).

Phosphoproteomics reveals major changes in substrate specificity caused by *PRKACA* mutations

Motivated by the results of the Western blot analysis and the *in silico* prediction, we used a quantitative phosphoproteomics approach to comprehensively analyze and quantitatively compare the substrate repertoires of wild-type and mutant PKA C α in mammalian cells. The three PKA C α mutations predicted to have the largest effects on substrate specificity were analyzed (Fig. 4). These included the frequent L206R mutation, the d244-248+E249Q mutation, which was predicted to have the strongest effect on substrate specificity, and the 200_201insV mutation, which shared prediction with the adjacent 199_200insW mutation. All cell lysates were obtained after 30-min stimulation with the adenylyl cyclase activator

330 forskolin to allow comparison under conditions of maximal PKA activity. The
331 phosphoproteomics analysis identified 463 sites phosphorylated by the wild-type C α subunit.
332 A direct quantitative comparison between wild-type and mutant C α subunits demonstrated
333 that the investigated *PRKACA* mutations caused major changes in the pattern of PKA
334 substrate phosphorylation (Fig. 4). These changes involved 62, 116 and 75 substrates that
335 were either hyper- or hypophosphorylated by the L206R, d244-248+E249Q and
336 200_201insV mutants, respectively, compared to wild-type (Fig. 4 and Supplementary Data,
337 Dataset S1 (23)). Our data also allowed us to compute sequence logos of the region
338 encompassing the phosphoacceptor site, where the size of the letters, each corresponding
339 to a given amino acid, indicates their relative frequency at a given position (Fig. 4). Overall,
340 the analysis showed relevant changes in the preferred amino acids surrounding the
341 RR/KXpS/T phosphorylation consensus sequence, including an increased preference for
342 amino acids with small or hydrophobic, non-aromatic side chains (glycine, alanine, valine,
343 methionine) at position +1 from the phosphoacceptor site, at the expense of phenylalanine
344 and other amino acids (Fig. 4). Moreover, we observed an increased preference for leucine
345 at position +1 from the phosphoacceptor site and an increased preference for acidic
346 residues in the residues downstream of the phosphoacceptor site for the L206R mutant,
347 consistent with a recent report by Lubner *et al.* in *E. coli* (29). Additionally, the L206R mutant
348 was characterized by a loss of preference for arginine residues at positions -7 to -4 relative
349 to the phosphoacceptor site and an increased preference for glutamic acid and serine at
350 several positions. For the d244-248+E249Q mutant, we found an increased preference for
351 leucine at position -1 from the phosphoacceptor site and a reduced preference for acidic
352 residues downstream of the phosphoacceptor site. The latter trend was mirrored in the
353 hypophosphorylated peptides, where acidic residues were overrepresented downstream of
354 the phosphoacceptor site. Interestingly, both mutants (L206R and d244-248+E249Q)
355 showed an asymmetric effect on substrate phosphorylation with a higher number of peptides
356 that were hyperphosphorylated (40 and 93, respectively) compared to a relatively lower

number of hypophosphorylated ones (22 and 23, respectively). Therefore, both mutations mainly seemed to increase the phosphorylation of poor substrates of the wild-type enzyme, while causing only smaller decreases in the phosphorylation of other substrates. For the 200_201insV mutant, we observed an increased preference for leucine and alanine at position -1, accompanied by a loss of preference for acidic residues downstream of the phosphoacceptor site and an increased preference for proline at position +3. The loss of preference for peptides containing acidic residues at downstream positions was reflected by their relative overrepresentation in the corresponding hypophosphorylated peptides (left panel). In contrast to the other two mutants, the 200_201insV mutant was characterized by a rather symmetric distribution with 35 hypo- and 40 hyperphosphorylated peptides, suggesting that comparable numbers of substrates were either hyper- or hypophosphorylated. In general, the phosphorylation patterns differed among the three C α mutants. However, four substrates were consistently found to be hyperphosphorylated by all three mutants compared to wild type. These were the citron rho-interacting kinase (CIT; Ser 480), the mitochondrial import receptor subunit TOM34 (Ser 93), histone H1.2 (Ser 36) and histone H1.4 (Ser 36) (Fig. 4). H1.2, H1.4, TOM34 and CIT were also found to be present and phosphorylated at the same sites in lysates of the cortisol-producing adrenocortical cell line NCI-H295R (Supplementary Data, Dataset S1 (23)).

To rule out that the observed changes were due to changes in protein levels rather than phosphorylation, we performed an additional proteomics experiment on the same cell lysates, which allowed us to directly compare the relative amounts of proteins at the proteome level between wild-type and mutant samples, including, importantly, H1.2, H1.4 and TOMM34 (Supplementary Data, Fig. S4, Dataset S2 (23)). The results indicate that the levels of most proteins, including H1.2, H1.4 and TOMM34, were unchanged between wild-type and mutant samples.

Whereas hyperphosphorylation of CIT and TOM34 might mediate some effects of *PRKACA* mutations, we concentrated our attention on H1 because phosphorylation by PKA of histone

H1.4 on Ser36 – and possibly of the highly homologous Ser36 site on H1.2 – is required for mitosis (20).

***PRKACA* mutations cause histone H1.4 hyperphosphorylation *in vitro* and in CPAs**

The conserved Ser36 phosphorylation site on histone H1 isoforms has been implicated in chromatin condensation and mitosis (20). This has been better studied for histone H1.4, which has been shown to be phosphorylated by PKA on Ser36 during mitosis, an event that has been demonstrated to induce histone H1.4 dissociation from chromatin and be required for mitosis (20). Because of the potential relevance of histone H1 Ser36 phosphorylation for the mechanism of action of *PRKACA* mutations, we first investigated histone H1.4 phosphorylation in HEK293A cells transfected with C α subunit mutants. In HEK293A cells, overexpression of the L206R mutant caused a strong increase (12-fold under basal conditions; 3-fold in the presence of forskolin) in histone H1.4 Ser36 phosphorylation compared to overexpression of wild-type C α (Fig. 5 and Supplementary Data, Fig. S5 (23)). Modestly increased levels of histone H1.4 Ser36 phosphorylation were also observed with the d244-248+E249Q and 200_201insV mutants compared with wild-type C α , even though these differences did not reach statistical significance (Fig. 5 and Supplementary Data, Fig. S5 (23)).

Furthermore, we analyzed histone H1.4 Ser36 phosphorylation in human CPA tumor samples of patients with Cushing's syndrome with or without *PRKACA* mutations (summary of clinical data in Supplementary Data, Table S1 (23)). Importantly, a 9-fold increase in histone H1.4 Ser36 phosphorylation was observed in CPAs carrying the L206R mutation compared with CPAs without *PRKACA* mutations (1.9 ± 0.26 vs. 0.21 ± 0.29 , $p=0.009$) (Fig. 6). These results indicated that in patients with adrenal Cushing's syndrome, at least the by far most frequent L206R mutation is associated with a strong increase of H1.4 phosphorylation in the patients' tumor tissue.

Discussion

Our results indicate that *PRKACA* mutations found in CPAs alter PKA preference for its targets, inducing hyperphosphorylation of several PKA substrates, including most notably histone H1.4 at Ser36, which has been suggested to play an essential role in mitosis (20). Thus, our study reveals another key mechanism that, together with increased PKA basal activity, might explain the development of CPAs in the presence of somatic *PRKACA* mutations (Supplementary Data, Fig. S6 (23)).

Whereas our previous study on the two *PRKACA* mutations initially identified in adrenal Cushing's syndrome (L206R and 199_200insW) showed that these mutations increase basal PKA activity by preventing the binding of R subunits, the present results obtained on a larger group of *PRKACA* mutations indicate that this is not always the case (see Supplementary Data, Fig. S7 (23) for a summary of the present results), and that a relative change in PKA substrate specificity likely contributes to the mechanism of action of *PRKACA* mutations.

Our phosphoproteomics analysis revealed four PKA substrates that were hyperphosphorylated by all three PKA C α mutants analyzed, and, thus, are potentially involved in the pathogenesis of CPAs due to *PRKACA* mutations. These included CIT (Ser 480), TOM34 (Ser 93), histone H1.2 (Ser 36) and histone H1.4 (Ser 36). Importantly, all four substrates were also identified to be expressed and phosphorylated on the same sites in lysates of NCI-H295R cells, which are widely used as a model of differentiated, cortisol-producing adrenocortical cells (Supplementary Data, Dataset S1 (23)). Of these, histone H1.4 and the highly homologous histone H1.2 appeared particularly intriguing because H1 histones play an important role in promoting, regulating and maintaining chromatin organization and, thus, are deeply involved in the regulation of gene transcription and mitosis (20,30-32). H1 histones possess a conserved serine residue at position 36 (Ser36), which has been mainly investigated for histone H1.4. Interestingly, histone H1.4 has been shown to be strongly phosphorylated on Ser36 by PKA at the first stage of mitosis

(prophase), to then rapidly revert to normal, low phosphorylation levels during cytokinesis (20). Phosphorylation of histone H1.4 on Ser36 has been shown to promote histone H1.4 dissociation from mitogenic DNA and induce changes in chromatin organization (20). Moreover, it has been shown that silencing H1.4 inhibits mitosis, an effect that cannot be rescued by a phosphorylation-deficient H1.4 mutant (S36A) (20). These findings indicate that the PKA-dependent phosphorylation of histone H1.4 at Ser36 plays an important role in promoting mitosis, presumably by inducing changes in chromatin structure that are required for the realization of the mitogenic program (20). Whereas other changes in the PKA phosphorylation pattern caused by *PRKACA* mutations might also play a role in the pathogenesis of CPAs, it is noteworthy that two of the four hyperphosphorylated sites shared by the three tested $C\alpha$ mutants are Ser36 on histone H1.4 and the corresponding Ser36 on histone H1.2, which likely plays a similar role. Our finding that histone H1.4 is highly hyperphosphorylated in CPAs carrying the L206R mutation – but not in those with wild-type PKA – supports a role of H1.4 hyperphosphorylation in the pathogenesis of CPAs due to *PRKACA* mutations. Further investigations, such as studies on chromatin organization by DAPI staining and H1.4–chromatin association by immunofluorescence (20) or chromatin immunoprecipitation will be required to further clarify the impact of the increased H1.4 (Ser36) phosphorylation on chromatin organization in *PRKACA* mutated CPA tissue.

In addition to hyperphosphorylation of histone H1, that of CIT and of TOM34 – which, to the best of our knowledge, have not been previously reported to be phosphorylated by PKA – might also play a role in the mechanism of action of *PRKACA* mutations. CIT is a serine/threonine-protein kinase that has been shown to be required for cytokinesis (33). Phosphorylation of Ser480 might potentially influence the activity of CIT and, thus, affect cytokinesis. TOM34 is involved in mitochondrial protein import (34). Interestingly, yeast TOM70 has been shown to be phosphorylated by PKA on Ser174 (35), which is homologous to Ser93 in human TOM34. In yeast, TOM70 phosphorylation by PKA inhibits its receptor activity, which results in reduced mitochondrial import of metabolite carriers (35).

Phosphorylation of TOM34 at Ser93 could have a similar effect. Future studies will be required to evaluate the role of CIT and TOM34 in the pathogenesis of CPAs.

The finding that *PRKACA* mutations cause histone H1.4 phosphorylation might help explaining why these mutations lead to the development of CPAs, while normal cAMP/PKA signaling such as resulting from physiological stimulation by the adrenocorticotrophic hormone (ACTH) has no or at most only mild proliferative effects on adrenocortical cells (36,37). Intriguingly, this may suggest that whereas an increase in PKA activity might be sufficient to induce excess cortisol production in the presence of *PRKACA* mutations, a change in PKA substrate preference – and the resulting hyperphosphorylation of histone H1.4 and possibly other targets involved in the control of cell replication – might be required to stimulate cell proliferation.

Finally, our findings indicate that, given the important changes in substrate specificity caused by *PRKACA* mutations, it might be possible to develop selective orthosteric PKA inhibitors that bind only to the mutant C α subunits and, thus, selectively inhibit the mutated PKA in CPAs without affecting the function of wild-type PKA in normal cells.

In summary, our findings indicate that *PRKACA* mutations found in CPAs lead to a change in the pattern of PKA phosphorylation, which might play an important role in their mechanism of action. This not only reveals a novel key mechanism potentially involved in the pathogenesis of CPAs and Cushing's syndrome, but might also allow the development of selective PKA inhibitors for therapeutic purposes that block mutated but not wild-type PKA. Moreover, these findings provide a highly illustrative example of how mutations altering substrate specificity of a protein kinase might cause a human disease, which might also have implications for other conditions.

488 **Author Contribution**

489 D.C. designed research with contributions from M.F. and A.S. K.B., I.W. and J.W. performed
490 research. K.B., I.W. and J.W. analyzed data. M.F., C.L.R. and S.S. provided tumor samples
491 together with clinical and genetic data. K.B. and D.C. wrote the paper with contributions from
492 M.F., A.S., I.W., C.L.R. and S.S.

493

494 **Acknowledgments**

495 We thank Bianca Klüpfel for excellent technical support and Ulrike Zabel for help with
496 cloning.

References

1. Calebiro D, Di Dalmazi G, Bathon K, Ronchi CL, Beuschlein F. cAMP signaling in cortisol-producing adrenal adenoma. *Eur J Endocrinol* 2015; 173:M99-106
2. Arnaldi G, Mancini T, Tirabassi G, Trementino L, Boscaro M. Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications. *J Endocrinol Invest* 2012; 35:434-448
3. Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, Tabarin A, Terzolo M, Tsagarakis S, Dekkers OM. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. *Eur J Endocrinol* 2016; 175:G1-G34
4. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. *Nat Rev Mol Cell Biol* 2002; 3:639-650
5. Taylor SS, Ilouz R, Zhang P, Kornev AP. Assembly of allosteric macromolecular switches: lessons from PKA. *Nat Rev Mol Cell Biol* 2012; 13:646-658
6. Sørberg K, Jahnsen T, Rognes T, Skålhegg BS, Laerdahl JK. Evolutionary Paths of the cAMP-Dependent Protein Kinase (PKA) Catalytic Subunits. *PLoS ONE* 2013; 8:e60935
7. Diskar M, Zenn H-M, Kaupisch A, Kaufholz M, Brockmeyer S, Sohmen D, Berrera M, Zaccolo M, Boshart M, Herberg FW, Prinz A. Regulation of cAMP-dependent Protein Kinases: The human protein kinase X (PrKX) reveals the role of the catalytic subunit α H- α I loop. *J Biol Chem* 2010; 285:35910-35918
8. Taylor SS, Buechler JA, Yonemoto W. cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes. *Annu Rev Biochem* 1990; 59:971-1005
9. Zhang P, Smith-Nguyen EV, Keshwani MM, Deal MS, Kornev AP, Taylor SS. Structure and Allostery of the PKA RII β Tetrameric Holoenzyme. *Science* 2012; 335:712-716

- 524 10. Beuschlein F, Fassnacht M, Assie G, Calebiro D, Stratakis CA, Osswald A, Ronchi
525 CL, Wieland T, Sbiera S, Faucz FR, Schaak K, Schmittfull A, Schwarzmayer T,
526 Barreau O, Vezzosi D, Rizk-Rabin M, Zabel U, Szarek E, Salpea P, Forlino A, Vetro
527 A, Zuffardi O, Kisker C, Diener S, Meitinger T, Lohse MJ, Reincke M, Bertherat J,
528 Strom TM, Allolio B. Constitutive activation of PKA catalytic subunit in adrenal
529 Cushing's syndrome. *N Engl J Med* 2014; 370:1019-1028
- 530 11. Di Dalmazi G, Kisker C, Calebiro D, Mannelli M, Canu L, Arnaldi G, Quinkler M,
531 Rayes N, Tabarin A, Laure Jullie M, Mantero F, Rubin B, Waldmann J, Bartsch DK,
532 Pasquali R, Lohse M, Allolio B, Fassnacht M, Beuschlein F, Reincke M. Novel
533 somatic mutations in the catalytic subunit of the protein kinase A as a cause of
534 adrenal Cushing's syndrome: a European multicentric study. *J Clin Endocrinol Metab*
535 2014; 99:E2093-2100
- 536 12. Ronchi CL, Dalmazi GD, Faillot S, Sbiera S, Assié G, Weigand I, Calebiro D,
537 Schwarzmayer T, Appenzeller S, Rubin B, Waldmann J, Scaroni C, Bartsch DK,
538 Mantero F, Mannelli M, Kastelan D, Chiodini I, Bertherat J, Reincke M, Strom TM,
539 Fassnacht M, Beuschlein F. Genetic Landscape of Sporadic Unilateral Adrenocortical
540 Adenomas Without *PRKACA* p.Leu206Arg Mutation. *J Clin Endocrinol Metab* 2016;
541 101:3526-3538
- 542 13. Calebiro D, Hannawacker A, Lyga S, Bathon K, Zabel U, Ronchi C, Beuschlein F,
543 Reincke M, Lorenz K, Allolio B, Kisker C, Fassnacht M, Lohse MJ. PKA catalytic
544 subunit mutations in adrenocortical Cushing's adenoma impair association with the
545 regulatory subunit. *Nat Commun* 2014; 5:5680
- 546 14. Cao Y, He M, Gao Z, Peng Y, Li Y, Li L, Zhou W, Li X, Zhong X, Lei Y, Su T, Wang
547 H, Jiang Y, Yang L, Wei W, Yang X, Jiang X, Liu L, He J, Ye J, Wei Q, Li Y, Wang W,
548 Wang J, Ning G. Activating hotspot L205R mutation in *PRKACA* and adrenal
549 Cushing's syndrome. *Science* 2014; 344:913-917

- 550 15. Goh G, Scholl UI, Healy JM, Choi M, Prasad ML, Nelson-Williams C, Kunstman JW,
551 Korah R, Suttorp A-C, Dietrich D, Haase M, Willenberg HS, Stalberg P, Hellman P,
552 Akerstrom G, Bjorklund P, Carling T, Lifton RP. Recurrent activating mutation in
553 *PRKACA* in cortisol-producing adrenal tumors. Nat Genet 2014; 46:613-617
- 554 16. Sato Y, Maekawa S, Ishii R, Sanada M, Morikawa T, Shiraishi Y, Yoshida K, Nagata
555 Y, Sato-Otsubo A, Yoshizato T, Suzuki H, Shiozawa Y, Kataoka K, Kon A, Aoki K,
556 Chiba K, Tanaka H, Kume H, Miyano S, Fukayama M, Nureki O, Homma Y, Ogawa
557 S. Recurrent somatic mutations underlie corticotropin-independent Cushing's
558 syndrome. Science 2014; 344:917-920
- 559 17. Nakajima Y, Okamura T, Gohko T, Satoh T, Hashimoto K, Shibusawa N, Ozawa A,
560 Ishii S, Tomaru T, Horiguchi K, Okada S, Takata D, Rokutanda N, Horiguchi J,
561 Tsushima Y, Oyama T, Takeyoshi I, Yamada M. Somatic mutations of the catalytic
562 subunit of cyclic AMP-dependent protein kinase (*PRKACA*) gene in Japanese
563 patients with several adrenal adenomas secreting cortisol [Rapid Communication].
564 Endocr J 2014; 61:825-832
- 565 18. Thiel A, Reis A-C, Haase M, Goh G, Schott M, Willenberg HS, Scholl UI. *PRKACA*
566 mutations in cortisol-producing adenomas and adrenal hyperplasia: a single-center
567 study of 60 cases. Eur J Endocrinol 2015; 172:677-685
- 568 19. Espiard S, Knape MJ, Bathon K, Assié G, Rizk-Rabin M, Faillot S, Luscap-Rondof W,
569 Abid D, Guignat L, Calebiro D, Herberg FW, Stratakis CA, Bertherat J. Activating
570 *PRKACB* somatic mutation in cortisol-producing adenomas. JCI Insight 2018; 3
- 571 20. Chu C-S, Hsu P-H, Lo P-W, Scheer E, Tora L, Tsai H-J, Tsai M-D, Juan L-J. Protein
572 Kinase A-mediated Serine 35 Phosphorylation Dissociates Histone H1.4 from Mitotic
573 Chromosome. J Biol Chem 2011; 286:35843-35851
- 574 21. Shechter D, Dormann HL, Allis CD, Hake SB. Extraction, purification and analysis of
575 histones. Nat Protocols 2007; 2:1445-1457

576 22. Safaei J, Mañuch J, Gupta A, Stacho L, Pelech S. Prediction of 492 human protein
577 kinase substrate specificities. *Proteome Sci* 2011; 9:1-13

578 23. Bathon K, Weigand I, Vanselow J, Ronchi C, Sbiera S, Schlosser A, Fassnacht M,
579 Calebiro D. Supplementary material for: Alterations in Protein Kinase A Substrate
580 Specificity as a Potential Cause of Cushing's Syndrome. Figshare Digital Repository
581 Deposited 29 August 2018. <https://figshare.com/s/20c9287aefcd6b69f28d>;

582 24. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized
583 p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat Biotech*
584 2008; 26:1367-1372

585 25. O'Shea JP, Chou MF, Quader SA, Ryan JK, Church GM, Schwartz D. pLogo: a
586 probabilistic approach to visualizing sequence motifs. *Nat Methods* 2013; 10:1211

587 26. Crooks GE, Hon G, Chandonia J-M, Brenner SE. WebLogo: A Sequence Logo
588 Generator. *Genome Res* 2004; 14:1188-1190

589 27. Gibson RM, Taylor SS. Dissecting the Cooperative Reassociation of the Regulatory
590 and Catalytic Subunits of cAMP-dependent Protein Kinase: role of Trp-196 in the
591 catalytic subunit. *J Biol Chem* 1997; 272:31998-32005

592 28. Smith CM, Radzio-Andzelm E, Madhusudan, Akamine P, Taylor SS. The catalytic
593 subunit of cAMP-dependent protein kinase: prototype for an extended network of
594 communication. *Prog Biophys Mol Biol* 1999; 71:313-341

595 29. Lubner JM, Dodge-Kafka KL, Carlson CR, Church GM, Chou MF, Schwartz D.
596 Cushing's syndrome mutant PKA^{L205R} exhibits altered substrate specificity. *FEBS Lett*
597 2017; 591:459-467

598 30. Fan YH, Nikitina T, Zhao J, Fleury TJ. Histone H1 depletion in mammals alters global
599 chromatin structure but causes specific changes in gene regulation. *Cell* 2005;
600 123:1199-1212

31. Kim K, Choi J, Heo K, Kim H, Levens D, Kohno K, Johnson EM, Brock HW, An W. Isolation and Characterization of a Novel H1.2 Complex That Acts as a Repressor of p53-mediated Transcription. *J Biol Chem* 2008; 283:9113-9126
32. Izzo A, Schneider R. The role of linker histone H1 modifications in the regulation of gene expression and chromatin dynamics. *Biochim Biophys Acta, Gene Regul Mech* 2016; 1859:486-495
33. Gruneberg U, Neef R, Li X, Chan EHY, Chalamalasetty RB, Nigg EA, Barr FA. KIF14 and citron kinase act together to promote efficient cytokinesis. *J Cell Biol* 2006; 172:363-372
34. Faou P, Hoogenraad NJ. Tom34: A cytosolic cochaperone of the Hsp90/Hsp70 protein complex involved in mitochondrial protein import. *Biochim Biophys Acta, Mol Cell Res* 2012; 1823:348-357
35. Schmidt O, Harbauer AB, Rao S, Eyrich B, Zahedi RP, Stojanovski D, Schonfisch B, Guiard B, Sickmann A, Pfanner N, Meisinger C. Regulation of mitochondrial protein import by cytosolic kinases. *Cell* 2011; 144:227-239
36. Calebiro D, Bathon K, Weigand I. Mechanisms of Aberrant PKA Activation by $C\alpha$ Subunit Mutations. *Horm Metab Res* 2017; 49:307-314
37. Fassnacht M, Hahner S, Hansen IA, Kreutzberger T, Zink M, Adermann K, Jakob F, Troppmair J, Allolio B. N-Terminal Proopiomelanocortin Acts as a Mitogen in Adrenocortical Tumor Cells and Decreases Adrenal Steroidogenesis. *J Clin Endocrinol Metab* 2003; 88:2171-2179

Figure legends

Fig. 1. Somatic *PRKACA* mutations identified in adrenal Cushing's Syndrome. (A)

Location of the identified *PRKACA* mutations in the crystal structure of the PKA holoenzyme. Note the clustering of the *PRKACA* mutations at the interface with the R subunit. The structure of the RII β :C α ₂ holoenzyme (Protein data bank/PDB entry 3TNP) was used as template. (B) Enlarged view of the PKA C α -RII β interface. Shown are the positions of residues affected by *PRKACA* mutations relative to the inhibitory sequence of RII β in the PKA RII β :C α ₂ holoenzyme. The inhibitory sequence of RII β interacts with active site cleft of C α and acts as a PKA substrate. Note the phosphorylated serine (S) residue within the canonical consensus for PKA phosphorylation (RRXS) in the inhibitory sequence. Most residues affected by *PRKACA* mutations participate directly or indirectly in substrate recognition. *, Residues affected by *PRKACA* mutations with largest predicted effects on substrate specificity based on *in silico* analysis. PDB entry 3TNQ was used as template.

Fig. 2. Effect of *PRKACA* mutations on the association of C α with R subunits.

HEK293A cells were co-transfected with FLAG-tagged RII β or RI α and either wild-type (WT) or mutant C α subunits. The association between C α and R subunits in the absence or presence of cAMP (200 μ M) was analyzed by co-immunoprecipitation. Samples were immunoprecipitated (IP) with an anti-FLAG antibody, followed by Western blot analysis with an antibody against C α . Western blot images were quantified by densitometric analysis. Data are mean \pm s.e.m. of three independent experiments. Arrows, mutants with conserved binding to R subunits. Differences are statistically significant by two-way ANOVA. *P<0.05, **P<0.01 and ****P<0.0001 vs. WT basal by Bonferroni's post hoc test. Representative Western blot images are shown in Supplementary Data, Fig. 1 (23).

Fig. 3. Effect of *PRKACA* mutations on PKA activity against a synthetic substrate.

HEK293A cells were co-transfected with RI α or RII β and either wild-type (WT) or mutant C α subunits. PKA activity in cell lysates was then measured against an artificial peptide substrate (kemptide) in the presence or absence of cAMP (40 μ M). The PKA activity measured in cells transfected with the empty expression vector (pcDNA) was subtracted. Data are mean \pm s.e.m. of three independent experiments. Data are statistically significant by two-way ANOVA. *P<0.05, ***P<0.001 vs. WT basal and ##P<0.01, ###P<0.001 vs. WT stimulated with cAMP by Bonferroni's post hoc test.

Fig. 4. *PRKACA* mutations affect substrate specificity as revealed by phosphoproteomics analysis. HEK293A cells were co-transfected with RII β and either wild-type (WT) or mutant C α subunits and labeled with light amino acids (WT) or heavy amino acids (mutant). Protein lysates from these cells were then proteolytically fragmented and the resulting phosphopeptides were immunoprecipitated using a phospho-PKA substrate antibody recognizing the RR/KXpS/T consensus. Phosphopeptides were separated and detected by nanoscale liquid chromatography coupled to tandem mass spectrometry (nano LC-MS/MS). Depicted are scatter plots showing the abundance of the detected phosphopeptides in the mutant relative to wild-type samples of three independent experiments. The sequence logos report, for each mutant, the relative amino acid preferences around the consensus motif (RR/KXpS/T) for both hypo- (left) and hyperphosphorylated (right) sequences, calculated from the phosphopeptides. Values are expressed as log₁₀-odds of the significance of overrepresentation versus the significance of underrepresentation, which are calculated using the binomial probability of residue frequencies.

Fig. 5. Effect of *PRKACA* mutations on histone H1.4 phosphorylation in HEK293A cells. HEK293A cells were co-transfected with wild-type (WT) or mutant PKA C α and the

R11 β subunit. Histone H1.4 phosphorylation was probed by Western blot analysis with an antibody specifically recognizing H1.4 phosphorylated at Ser36. A Western blot analysis for total histone H1.4 was used as loading control. Western blot images were quantified by densitometric analysis. The adenylyl cyclase activator forskolin (10 μ M) was used to induce maximal PKA activity. Data are mean \pm s.e.m of three independent experiments. Differences are statistically significant by two-way ANOVA. *** $P<0.001$ vs. WT basal and # $P<0.05$ vs. WT forskolin by Bonferroni's post hoc test.

Fig. 6. Effect of *PRKACA* mutations on histone H1.4 phosphorylation in tumor (CPA) samples from patients with adrenal Cushing's syndrome. Histones were extracted from CPAs with or without *PRKACA* mutations and analyzed by Western blot analysis with an antibody specifically recognizing H1.4 phosphorylated at Ser36. A Western blot analysis for total histone H1.4 was used as loading control. Western blot images were quantified by densitometric analysis. Quantified data are mean \pm s.e.m of 3 and 4 CPAs carrying the L206R mutation or with *PRKACA* wild-type (WT), respectively. Differences are statistically significant by unpaired t-test (** $P=0.009$).

Table 1. List of somatic *PRKACA* mutations identified so far in CPAs of patients with overt Cushing's syndrome. Bold, studies by our group.

Tables

Mutation	Frequency (n mutated/total)	Reference
L206R	36% (21/59)	(10)
	60% (33/55)	(16)
	67% (84/126)	(14)
	35% (13/37)	(15)
	23% (3/13)	(17)
	34% (22/64)	(11)
	31% (11/35)	(18)
199_200insW	2% (1/59)	(10)
200_201insV	5% (3/64)	(11)
S213R+insIIIR	2% (1/64)	(11)
W197R	3% (1/39)	(12)
d244-248+E249Q	3% (1/39)	(12)
E32V	3% (1/39)	(12)

Figures




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6